Helix Fund
VC Fund
Chicago, United States
Helix Fund is a real estate investment management company based in Chicago, United States.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Helix Fund invests in
Stages Helix Fund invests in
Countries Helix Fund invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David A. Helfand
|
|||
Investment Focus
Industry
- Health Care 4 (80%)
- Biotechnology 4 (80%)
- Apps 1 (20%)
- Medical 1 (20%)
- Diabetes 1 (20%)
Stage
- Funding Round 2 (40%)
- Seed 1 (20%)
- Series A 1 (20%)
- Post-IPO Equity 1 (20%)
Country
- United States 4 (80%)
- Hong Kong 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
David A. Helfand
Founder and CEO
|
Founder and CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Animoca Brands is a metaverse and gaming venture capital firm that focuses on driving digital property rights to gamers and internet users through NFTs. It utilizes gamification and blockchain to develop and market a portfolio of mobile applications, games, and additional products oriented to educational learning to ensure transparency, security,and new business models. | $2.5M / Post-IPO Equity / May 22, 2019 | ||
| Euclises Pharmaceuticals, Inc is developing novel pain and cancer medications that offer superior safety margins compared to existing drugs. The company is based on new inventions from Dr. John Talley, the most accomplished medicinal chemist in the world. Dr. Talley previously invented Celebrex and seven other approved drugs. New compounds fromEuclises will offer both improved efficacy and safety relative to existing therapies. Euclises is located at the BioGenerator Accelerator Labs. | Sep 23, 2015 | ||
SynerZ Medical
|
SynerZ Medical, Inc. develops medical device for the treatment of obesity and type 2 diabetes. The company was incorporated in 2013 and is based in St. Louis, Missouri. | $650K / Seed / Feb 24, 2015 | |
| MediBeacon is an optical diagnostic company providing clinicians with critical information that improve patient care. Its mission is to commercialize biocompatible optical diagnostic agents for physiological monitoring, surgical guidance, and imaging of pathological disease in the human population. Several product concepts in these areas arecontained in the MediBeacon Intellectual Property (IP) portfolio.The product pipeline includes real-time kidney function monitoring, a huge leap forward in the world of nephrology. The clinical history and road to FDA and European approvals on this component of the MediBeacon pipeline as well as other developments related to the platform of fluorescent agents and their potential clinical application. | Mar 18, 2013 | ||
| CLS is a drug discovery company focusing on rational drug design to discover and develop mechanistically novel kinase inhibitors for use in both human and animal health care. CLS’s kinase inhibitors target key signal transduction enzymes involved in the regulation of cancer growth and survival, or in the modulation of chronic inflammation. Unlikemany other kinase inhibitor programs, however, CLS is targeting novel binding sites (on kinase targets that have proved challenging) as well as previously “un-drugged” kinases. Driving CLS success in this effort is a team of world-class experts with extensive Pharma experience in kinase inhibitor discovery and development. CLS provides this team with the opportunity to pursue strategies and targets outside Pharma’s traditional focus. In addition, scientific and business collaborations are being established to enable the success of the business. The strategy is to develop and maintain a program pipeline: discover, develop, partner, repeat. | $4M / Series A / Sep 17, 2012 |
Co-Investors
BioGenerator
4 deals together
Missouri Technology Corporation
2 deals together
ABC Laboratories
1 deal together
Cultivation Capital
1 deal together
DFJ Mercury
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Helix Fund invest in?
Helix Fund invests primarily in Health Care, Biotechnology and Apps startups, most often at Funding Round and Seed stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Helix Fund?
Public channels for Helix Fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Helix Fund?
The team at Helix Fund includes David A. Helfand (Founder and CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
